The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2022 | Assessing the benefits of HIPEC in GI cancers
Deepa Magge, MD, FACS, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses whether there is still a role for hyperthermic intraperitoneal chemotherapy (HIPEC) in treating gastrointestinal cancers with the presence of cytoreductive surgery. The Phase III PRODIGE trial (NCT00769405) concluded that addition of HIPEC to cytoreductive surgery did not improve outcomes in colorectal peritoneal metastases. However, further research is needed, where mitomycin C was used in the trial and oxaliplatin is the standard chemotherapy of choice for HIPEC in America. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
